Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 92 | ETA2023 | Next issue

45th Annual Meeting of the European Thyroid Association (ETA) 2023

Poster Presentations

Graves’ Disease

ea0092ps1-02-01 | Graves’ Disease | ETA2023

Preoperative management of graves’ disease: should all patients be euthyroid?

Tomoda Chisato , Ono Reiko , Yoshioka Kana , Saito Yoshiyuki , Masaki Chie , Akaishi Junko , Hames Yamada Kiyomi , Okamura Ritsuko , Suzuki Akifumi , Matsuzu Ken-ichi , Kitagawa Wataru , Sugino Kiminori , Ito Koichi

Context: Prior to thyroidectomy for Graves’ disease, thyroid function should be adequately controlled to avoid complications such as thyroid storm. However, preoperative thyroid function control is sometimes difficult.Objective: This study assessed the postoperative risks are increased or not if biochemically hyperthyroid patients undergoing total thyroidectomy in comparison to euthyroid patients.Methods: A retrospective, coho...

ea0092ps1-02-02 | Graves’ Disease | ETA2023

Predetermined vs calculated 131I activity for the treatment of patients with graves’ disease: which is the best?

Arcidiacono Francesco , Barca Ignazio , Prinzi Antonio , Scuto Andrea , Volpe Salvatore , Piticchio Tommaso , Malandrino Pasqualino , Frasca Francesco , Belfiore Antonino

Background: Graves’ disease (GD) is an autoimmune disorder of thyroid gland and is the first cause of hyperthyroidism. Radioactive iodine (RAI) therapy is the most used second- line treatment after failure of anti-thyroid drugs. The optimal RAI’s activity to be administered may be predetermined or calculated. Whether the latter is better is still a matter of debate.Aim: To compare the risk of persistent hyperthyroidism in GD patients treated wi...

ea0092ps1-02-03 | Graves’ Disease | ETA2023

Analysis of cost and treatment effects in the care given for graves disease - a swedish cost-utility analysis

Lindholm Lars , Sjolin Gabriel , Jonsson Annika , Wallin Goran , Filipsson Nystrom Helena

Background: Guidelines in healthcare shall be evidence-based, satisfy patients’ needs and improve patients’ outcomes. We aimed to estimate incremental costs after the introduction of a national guideline for Graves’ disease in Sweden adding the Graves’ Recurrent Events After Therapy (GREAT) score with genetic determinants to predict recurrence, a thyroid nurse, calcium-D-vitamin treatment preoperatively, and thyroid stimulating immunoglobulins.<p class=...

ea0092ps1-02-04 | Graves’ Disease | ETA2023

The relationship between mental fatigue, anxiety and depression in graves disease

Holmberg Mats , Berglund Peter , Johansson Birgitta , Malmgren Helge , Skau Simon , Filipsson Nystrom Helena , Jonsson Annika

Background: Mental fatigue, depression and anxiety are common in Graves’ disease (GD). Our aims were to assess the relationship between these variables among GD patients both in the hyperthyroid phase and after treatment. The pathogenic mechanisms involved in these symptoms are unknown and so is if previous psychiatric disease influences these symptoms.Methods: This was a longitudinal case control study in Göteborg, Sweden, on 65 women with new...

ea0092ps1-02-05 | Graves’ Disease | ETA2023

Association between radioactive iodine treatment and cancer risk in graves’ disease: a nationwide cohort study

Jin Kim Kyeong , Lee Yeji , Won Park Da , Jin Kim Kyoung , Seon Park Min , Hyung Kim Joo , Young Kim Hee , Hoon Kim Nam , Choi Jimi , Yub Kim Hun , Baek Seung-kuk , Yoon Jung Kwang , Gon Kim Sin

Objectives: Radioactive iodine (RAI) therapy has potential therapeutic effects in treating Graves’ disease (GD). However, whether RAI therapy for GD can increase cancer risk remains a controversial issue in medicine and public health.Methods: Using the Korean National Health Insurance Service-National Health Information Database (NHIS-NHID, 2002–2020), we investigated hazard ratios (HRs) of overall and site-specific cancer associated with RAI i...

ea0092ps1-02-06 | Graves’ Disease | ETA2023

The role of selenium supplement in graves disease - a case report

Haxhiraj Adela , Poshi Klodiana , Hoxha Violeta , Kermaj Marjeta , Ylli Dorina

Introduction: Selenium is a mineral that plays a key role in the intracellular reactions of the thyroid. Some selenium-based proteins have a protective antioxidant function in thyrocytes. Likewise, Selenium is incorporated into deiodinases, helping in the synthesis of thyroid hormones. Through its antioxidant and anti inflammatory properties, selenium affects the development of autoimmune thyroid diseases, such as Graves Disease. Supplementation with selenium is often prescrib...

ea0092ps1-02-07 | Graves’ Disease | ETA2023

Agranulocitosis caused by methimazole in a patient with graves’ disease and multiple myeloma

Kermaj Marjeta , Biba Valbona , Poshi Klodiana , Ylli Dorina , Hoxha Violeta , Ylli Agron

Introduction: Multiple myeloma (MM) is a lethal hematological malignancy with an incidence of 6.1/100 000 per year. The association of thyroid autoimmune diseases and MM is rare and has not been fully investigated. Also, it is well known that agranulocytosis is a potential lethal adverse reaction of antithyroid treatment.Case report: We present the case of a 59-year-old female patient that presented with symptoms of hyperthyroidism. Objectively: Mild bil...

ea0092ps1-02-08 | Graves’ Disease | ETA2023

Evaluation of paraoxonase (PON-1) activity and advanced glycation end-products (AGES) as reliable markers of oxidative stress in graves’ disease patients

Lagana Martina , Teresa Cristani Maria , Sofia Molonia Maria , Burduja Nina , Campenni Alfredo , Cannavo Salvatore , Ruggeri Rosaria

Objective: Oxidative stress has been implicated in the pathogenesis of hyperthyroidism, and its complications. Advanced glycation end products (AGEs), compounds derived from non-enzymatic transformation of macromolecules, are able to increase oxidative stress and promote inflammation and are increased in several oxidative stress-related disorders, including autoimmune thyroiditis. In the same diseases, the activity of paraoxonase-1 (PON-1), an anti-oxidant enzyme protecting ag...

ea0092ps1-02-09 | Graves’ Disease | ETA2023

Patients` experience of being affected by graves`disease-the initial 3 month-phase

Lindo Agneta , Rivera Johansson Angelica , Fors Andreas , Filipsson Nystrom Helena

Background: Graves’ disease (GD) is the most common form of hyperthyroidism in Sweden. About 2000 patients are affected by GD annually (incidence 21/100 000) and a majority are women in working age. GD can be overwhelming for the affected patient. Health care professionals do their best to meet the patients’ needs, but can we do more? The aim of this study was to explore patients’ experiences of being affected by GD to improve healthcare.M...